Immunitybio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials With Anktiva® and Checkpoint Immunotherapy at World Conference on Lung Cancer
Immunitybio在非小細胞肺癌患者中提出了陽性的長期總生存數據，並宣佈在世界肺癌大會上使用Anktiva®和免疫檢查點治療進行註冊意向第三期臨床試驗
